No connection

Search Results

AKAN vs HCWB

AKAN
Akanda Corp.
BEARISH
Price
$0.82
Market Cap
$1.7M
Sector
Healthcare
AI Confidence
95%
HCWB
HCW Biologics Inc.
BEARISH
Price
$0.36
Market Cap
$2.5M
Sector
Healthcare
AI Confidence
98%

Valuation

P/E Ratio
AKAN
0.01
HCWB
--
Forward P/E
AKAN
--
HCWB
-0.66
P/B Ratio
AKAN
0.04
HCWB
-0.45
P/S Ratio
AKAN
2.06
HCWB
45.26
EV/EBITDA
AKAN
0.55
HCWB
-0.58

Profitability

Gross Margin
AKAN
24.91%
HCWB
20.0%
Operating Margin
AKAN
-443.84%
HCWB
-18370.3%
Profit Margin
AKAN
-266.31%
HCWB
0.0%
ROE
AKAN
-60.86%
HCWB
--
ROA
AKAN
-28.69%
HCWB
-31.19%

Growth

Revenue Growth
AKAN
--
HCWB
-93.2%
Earnings Growth
AKAN
--
HCWB
--

Financial Health

Debt/Equity
AKAN
0.12
HCWB
2.46
Current Ratio
AKAN
1.25
HCWB
0.11
Quick Ratio
AKAN
0.89
HCWB
0.09

Dividends

Dividend Yield
AKAN
--
HCWB
--
Payout Ratio
AKAN
0.0%
HCWB
0.0%

AI Verdict

AKAN BEARISH

AKAN exhibits severe financial distress, evidenced by a Piotroski F-Score of 3/9 (indicating weak operational health) and a lack of an Altman Z-Score, which raises red flags for potential bankruptcy risk. The company is unprofitable with negative margins across all key metrics, including a staggering -266.31% profit margin and -60.86% ROE. Despite a low Price/Book of 0.04 and a Graham Number of $281.01, the stock trades at $0.82—well below fair value—due to extreme operational failure and lack of sustainable growth. The 52-week price range shows a collapse from $46.45 to $0.81, reflecting a 100% decline over five years and confirming deep investor skepticism.

Strengths
Graham Number suggests a defensive fair value of $281.01
Low Price/Book ratio (0.04) indicates potential undervaluation on asset basis
Debt/Equity ratio of 0.12 suggests conservative capital structure
Risks
Piotroski F-Score of 3/9 signals weak financial health and operational inefficiency
Negative profit, operating, and return metrics across the board (ROE: -60.86%, ROA: -28.69%)
No revenue or earnings growth data available, suggesting stagnation or collapse
HCWB BEARISH

HCWB exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.11 and a catastrophic revenue collapse of -93.20% YoY. With a negative Price-to-Book ratio (-0.45) and an operating margin of -18370.31%, the firm is effectively eroding its remaining capital. The stock's 96% decline over the past year reflects a market pricing in a high probability of insolvency.

Strengths
Positive Gross Margin (20%)
Single analyst target price ($2.00) suggests theoretical upside
Recent 1-week short-term price bounce (+36%)
Risks
Extreme liquidity risk (Current Ratio 0.11)
Catastrophic revenue decline (-93.20% YoY)
Negative shareholder equity (Price/Book -0.45)

Compare Another Pair

AKAN vs HCWB: Head-to-Head Comparison

This page compares Akanda Corp. (AKAN) and HCW Biologics Inc. (HCWB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile